Latest news with #JulianHarrison
Business Wire
22-07-2025
- Business
- Business Wire
BTIG to Host Virtual Biotechnology Conference on July 29-30, 2025
NEW YORK--(BUSINESS WIRE)-- BTIG announced today that it will hold its annual Biotechnology Conference on Tuesday, July 29 th through Wednesday, July 30 th, 2025. The virtual event will host over 70 established and emerging healthcare company management teams for one-on-one investor meetings and thematic panel discussions with industry leaders. Panel themes will include lupus, pulmonary hypertension, emerging trends in inflammatory bowel disease and irritable bowel syndrome, latest developments in CML and CLL, role of blood-based biomarkers and more. The conference will be hosted by: Julian Harrison, BTIG Biotechnology Analyst Jeet Mukherjee, PhD, BTIG Biotechnology Analyst Thomas Shrader, PhD, CFA, BTIG Biotechnology Analyst Justin Zelin, BTIG Biotechnology Analyst 'Our team at BTIG is excited to deliver another engaging biotechnology conference that connects visionary industry leaders and institutional investors,' commented Ryan Serwin, CFA, Director of Research at BTIG. 'We are looking forward to collaborative discussions that explore the therapeutic areas, development pipelines, and technological advancements shaping this sector today.' For more information about the conference, email USCorporateAccess@ Please note that participants must be pre-registered to attend. To access BTIG insights, contact a firm representative or log in to The conference is being produced by BTIG's Corporate Access program which hosts client events across the consumer, energy and infrastructure, financials, healthcare, industrials, real estate and technology sectors. About BTIG BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 700 employees, BTIG, LLC and its affiliates operate out of 20 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities. The firm's core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.
Yahoo
16-07-2025
- Business
- Yahoo
BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best oversold NASDAQ stocks to buy now. On July 11, BTIG analyst Julian Harrison maintained a Buy rating on Apogee Therapeutics Inc. (NASDAQ:APGE), raising the price target to $115 from $100. A biotechnologist in a white lab coat manipulating genes in a laboratory. The analyst told investors in a research note that the new EASI-75 watermark for Biologics in Atopic Dermatitis surpassed expectations, supporting a market-leading profile and painting a positive picture for the company. Apogee Therapeutics Inc. (NASDAQ:APGE) has $681.4 million in cash, cash equivalents, and marketable securities as of March 31. Based on the company's current operating plans, management expects its existing cash, cash equivalents and marketable securities to support its operating expenses into the first quarter of 2028. Apogee Therapeutics Inc. (NASDAQ:APGE) is a biotechnology company that offers treatments for chronic obstructive pulmonary disease (COPD), atopic dermatitis (AD), and associated inflammatory and immunology (I&I) indications. While we acknowledge the potential of APGE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
27-06-2025
- Business
- Business Insider
BTIG Sticks to Their Buy Rating for Theravance Biopharma (TBPH)
In a report released today, Julian Harrison from BTIG maintained a Buy rating on Theravance Biopharma (TBPH – Research Report), with a price target of $25.00. The company's shares closed today at $10.73. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Harrison is a 4-star analyst with an average return of 4.1% and a 43.80% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Theravance Biopharma, and Tvardi Therapeutics. Currently, the analyst consensus on Theravance Biopharma is a Moderate Buy with an average price target of $18.75, which is a 74.74% upside from current levels. In a report released today, JonesTrading also reiterated a Buy rating on the stock with a $24.00 price target.
Globe and Mail
19-06-2025
- Business
- Globe and Mail
Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE – Research Report) and UnitedHealth (UNH – Research Report) with bullish sentiments. Confident Investing Starts Here: Spyre Therapeutics (SYRE) BTIG analyst Julian Harrison maintained a Buy rating on Spyre Therapeutics yesterday and set a price target of $70.00. The company's shares closed last Tuesday at $15.18. According to Harrison is a 3-star analyst with an average return of 1.1% and a 41.2% success rate. Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Rani Therapeutics Holdings, and Mereo Biopharma Group Plc. ;'> The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spyre Therapeutics with a $56.83 average price target, implying a 237.1% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $50.00 price target. UnitedHealth (UNH) Bernstein analyst Lance Wilkes assigned a Buy rating to UnitedHealth yesterday and set a price target of $377.00. The company's shares closed last Tuesday at $308.87. According to Wilkes is a 2-star analyst with an average return of 0.0% and a 41.3% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Elevance Health, and HCA Healthcare. ;'> Currently, the analyst consensus on UnitedHealth is a Moderate Buy with an average price target of $367.68, representing a 19.6% upside. In a report issued on June 2, KeyBanc also maintained a Buy rating on the stock with a $400.00 price target.
Yahoo
09-05-2025
- Business
- Yahoo
J&J's oral psoriasis drug helps patients achieve clear skin in late-stage study
(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the once-daily pill helped patients achieve clear or almost clear skin. The drugmaker has been working on more convenient treatment options as its injectable psoriasis drug Stelara, which gained over $10 billion in sales last year, faces stiff competition from cheaper rivals. J&J said last month it expects the drug, icotrokinra, to generate sales of $700 million in 2028. BTIG analyst Julian Harrison expects icotrokinra to "complement rather than disrupt" market leaders, including J&J's Tremfya and AbbVie's Skyrizi. Icotrokinra helped 66% of patients with scalp psoriasis and 77% of those with genital psoriasis achieve significantly clear skin compared to 11% and 21% success rate in patients on placebo, respectively, J&J said. The drug was administered to patients 12 years and older with at least moderate plaque psoriasis affecting "high-impact" areas, including the scalp and genitals, for 16 weeks. Plaque psoriasis, an immune-mediated condition characterized by thick, scaly patches or plaques, is the most common type of psoriasis. Psoriasis is estimated to affect more than 7.5 million adults in the United States. The study enrolled 311 patients, who were randomly chosen to receive either icotrokinra or placebo for a period of 16 weeks. J&J is developing the drug with partner Protagonist Therapeutics. Icotrokinra is designed to block a protein, IL-23, involved in inflammatory responses and is being tested as a potential treatment for other inflammatory conditions, such as ulcerative colitis. In a separate late-stage study last year, the drug showed significant skin clearance in patients with moderate-to-severe plaque psoriasis. Sign in to access your portfolio
